Hims & Hers Health, Inc. (NYSE:HIMS) Receives $20.29 Consensus Price Target from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.29.

HIMS has been the subject of a number of research analyst reports. Jefferies Financial Group upped their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Bank of America upped their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $24.50, for a total value of $183,750.00. Following the sale, the insider now directly owns 185,326 shares in the company, valued at approximately $4,540,487. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, COO Melissa Baird sold 11,749 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $14.65, for a total value of $172,122.85. Following the sale, the chief operating officer now directly owns 585,800 shares in the company, valued at approximately $8,581,970. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $24.50, for a total transaction of $183,750.00. Following the sale, the insider now owns 185,326 shares in the company, valued at $4,540,487. The disclosure for this sale can be found here. In the last three months, insiders have sold 753,292 shares of company stock worth $13,557,329. 17.71% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently made changes to their positions in the business. Cim LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at about $1,445,000. Sanctuary Advisors LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at about $415,000. Creative Planning bought a new position in Hims & Hers Health during the 2nd quarter valued at about $443,000. Scientech Research LLC bought a new position in Hims & Hers Health during the 2nd quarter valued at about $1,474,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Hims & Hers Health by 44.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 116,477 shares of the company’s stock valued at $2,352,000 after purchasing an additional 36,081 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Up 2.3 %

Shares of NYSE:HIMS opened at $13.96 on Friday. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The firm has a 50-day simple moving average of $18.21 and a 200 day simple moving average of $16.89. The company has a market cap of $3.00 billion, a PE ratio of -1,396.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS. As a group, research analysts forecast that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.